EDAP Reports Record Q4 & FY25 HIFU Revenue, Reiterates Strong 2026 Guidance

summarizeSummary

EDAP TMS SA announced strong Q4 and full-year 2025 HIFU business growth, including record system placements and procedure growth, while reiterating its positive 2026 revenue guidance, despite an overall net loss increase.

check_boxKey Events

• Record HIFU Revenue Growth

  Q4 2025 HIFU revenue increased 34% year-over-year to $13.5 million, with full-year 2025 HIFU revenue up 39% year-over-year to $37.4 million.

• Strong Focal One Adoption

  Achieved a quarterly record of 15 net system placements in Q4 2025 and 69% full-year year-over-year growth in Focal One system placements, alongside 28% Q4 year-over-year growth in U.S. procedures.

• Reiterated 2026 Guidance

  Company reaffirmed its 2026 total revenue guidance of $72.0 million to $80.0 million, with core HIFU business revenue expected to grow 34% to 45% year-over-year.

• Widened Net Losses

  Reported a Q4 2025 net loss of $9.5 million (compared to $2.0 million in Q4 2024) and a full-year 2025 net loss of $29.2 million (compared to $20.6 million in FY 2024).

auto_awesomeAnalysis

This filing highlights robust performance in EDAP's core High-Intensity Focused Ultrasound (HIFU) business, with significant year-over-year revenue growth, system placements, and U.S. procedure growth for Focal One. This indicates strong market adoption and execution in their strategic focus area. While overall company revenue saw a slight decrease and net losses widened due to a decline in non-core businesses and increased operating expenses, the reiterated strong 2026 HIFU revenue guidance provides a positive outlook for the company's future. Investors will likely focus on the continued expansion and profitability potential of the HIFU segment, despite the current cash burn.